Cargando…

No Dopamine Agonist Modulation of Brain [(18)F]FEOBV Binding in Parkinson’s Disease

[Image: see text] The [(18)F]fluoroethoxybenzovesamicol ([(18)F]FEOBV) positron emission tomography (PET) ligand targets the vesicular acetylcholine transporter. Recent [(18)F]FEOBV PET rodent studies suggest that regional brain [(18)F]FEOBV binding may be modulated by dopamine D2-like receptor agen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albin, Roger L., Kanel, Prabesh, van Laar, Teus, van der Zee, Sygrid, Roytman, Stiven, Koeppe, Robert A., Scott, Peter J. H., Bohnen, Nicolaas I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983523/ https://www.ncbi.nlm.nih.gov/pubmed/35289620 http://dx.doi.org/10.1021/acs.molpharmaceut.1c00961

Ejemplares similares

Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [(18)F]FEOBV PET study
por: Kanel, Prabesh, et al.
Publicado: (2022)

Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson’s disease: Results from a data-driven approach
por: van der Zee, Sygrid, et al.
Publicado: (2022)

Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [(18)F]-FEOBV
por: Nejad-Davarani, Siamak, et al.
Publicado: (2018)

Regional serotonin terminal density in aging human brain: A [(11)C]DASB PET study
por: Kanel, Prabesh, et al.
Publicado: (2023)

Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022)

Cholinergic centro-cingulate network in Parkinson disease and normal aging
por: Bohnen, Nicolaas I., et al.
Publicado: (2023)

Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment
por: van der Zee, Sygrid, et al.
Publicado: (2022)

Effect of Dopamine D(2) Receptor Antagonists on [(18)F]-FEOBV Binding
por: Schildt, Anna, et al.
Publicado: (2020)

Cholinergic system changes of falls and freezing of gait in Parkinson's disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2019)

Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease
por: Bohnen, Nicolaas I, et al.
Publicado: (2021)

Cholinergic Depletion in Alzheimer's Disease Shown by [(18)F]FEOBV Autoradiography
por: Parent, Maxime J., et al.
Publicado: (2013)

Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology
por: Boertien, Jeffrey M., et al.
Publicado: (2020)

In vivo vesicular acetylcholine transporter density in human peripheral organs: an [(18)F]FEOBV PET/CT study
por: Horsager, Jacob, et al.
Publicado: (2022)

Ketogenic interventions in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease: A systematic review and critical appraisal
por: Bohnen, Jeffrey L. B., et al.
Publicado: (2023)

Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2010)

Fatigue in Parkinson’s Disease Associates with Lower Ambulatory Diastolic Blood Pressure
por: Kotagal, Vikas, et al.
Publicado: (2019)

First-in-human imaging and kinetic analysis of vesicular acetylcholine transporter density in the heart using [(18)F]FEOBV PET
por: Saint-Georges, Zacharie, et al.
Publicado: (2020)

The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [(11)C]DASB PET Imaging Study
por: Lelieveld, Irene M., et al.
Publicado: (2012)

Introduction: The Gut-Brain Axis in Parkinson’s Disease
por: van Laar, Teus
Publicado: (2019)

Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [(18)F]FEOBV and choline acetyltransferase immunochemistry
por: Parent, Maxime J, et al.
Publicado: (2013)

Reduced cortical cholinergic innervation measured using [(18)F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment
por: Xia, Ying, et al.
Publicado: (2022)

Automated Synthesis of (18)F-BCPP-EF {2-tert-Butyl-4-Chloro-5-{6-[2-(2[(18)F]fluoroethoxy)-Ethoxy]-Pyridin-3-ylmethoxy}-2H-Pyridazin-3-One for Imaging of Mitochondrial Complex 1 in Parkinson’s Disease
por: Kaur, Tanpreet, et al.
Publicado: (2022)

Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
por: Boertien, Jeffrey M., et al.
Publicado: (2022)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Ketogenic-Mimicking Diet as a Therapeutic Modality for Bipolar Disorder: Biomechanistic Rationale and Protocol for a Pilot Clinical Trial
por: Bohnen, Jeffrey L. B., et al.
Publicado: (2023)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Infusion Therapies in the Treatment of Parkinson’s Disease
por: van Laar, Teus, et al.
Publicado: (2023)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Sleep Disturbance as Potential Risk and Progression Factor for Parkinson’s Disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2019)

Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

Pathological gambling and dopamine agonists: A phenotype?
por: Pinder, Roger M
Publicado: (2007)

The Non-Anhydrous, Minimally Basic Synthesis of the Dopamine D(2) Agonist [18F]MCL-524
por: Inkster, James A. H., et al.
Publicado: (2021)

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease
por: van der Vegt, Joyce P.M., et al.
Publicado: (2020)

Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease
por: Chou, Kelvin L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ul0bsg5u39r2pseifhmn9cien